Page 3 - Post Approval Commitment News Today : Breaking News, Live Updates & Top Stories | Vimarsana

A vial of the Pfizer-BioNTech Covid-19 vaccine. File.   | Photo Credit: AFP Pfizer, which is ready to offer 5 crore doses to India between July and October this year and has sought certain relaxations including indemnification Seeking a fast-track approval for its COVID-19 vaccine, U.S. major Pfizer has told Indian authorities that its jab has shown “high effectiveness” against the SARS-CoV-2 variant prevalent in India and on people of Indian ethnicity or nationality, while it is suitable for everyone aged 12 years or above and can be stored for a month at 2-8 degrees, sources said on W...

In its latest communication to the government, Pfizer has also thanked the Government of India to have agreed to its request for procurement through a central government pathway and to discuss "the Indemnity and Liability protection". "The timely alignment and execution of the draft Heads of Terms will enable Pfizer to reserve the allocation of doses and pave the pathway for executing the Distribution and Supply Agreement," the company told the government while seeking fast-tracking the regulatory pathway to help it supply "Pfizer's COVID-19 vaccine as expeditiously as possible to India". Pfi...

Pfizer has sought certain relaxations including indemnification

NEW DELHI: Seeking a fast-track approval for its Covid-19 vaccine, US major Pfizer has told Indian authorities that its jab has shown "high effectiveness" against the SARS-CoV-2 variant prevalent in India and on people of Indian ethnicity or nationality, while it is suitable for everyone aged 12 years or above and can be stored for a month at 2-8 degrees, sources said on Wednesday. Pfizer, which is ready to offer 5 crore doses to India between July and October this year and has sought certain relaxations including indemnification, has held a series of interactions with the Indian government ...

Pfizer, which is ready to offer 5 crore doses to India between July and October this year and has sought certain relaxations including indemnification, has held a series of interactions with the Indian government authorities recently including one this week, during which it shared the most recent data points regarding efficacy trials and approvals for its vaccine in various countries and by the WHO.